In a surprising move, Eli Lilly discontinued further development of a cholesterol-lowering treatment that some Wall Streeters thought would become a blockbuster medicine. A data monitoring committee determined that the drug, known as evacetrapib, simply wasn’t working and so was unlikely to meet the primary endpoint in a key late-stage clinical trial.
Read Full Article »
